|
 |
Volume 4, Number 5, Supplement 2 (May 2007) | |||||
| Irinotecan: A Decade of Difference | |||||
Contents |
|||||
3 |
Treatment of colorectal cancer since the introduction of irinotecan Keck School of Medcine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA A panel explores the preferred approaches to managing metastatic colorectal cancer.
|
||||
5 |
The chemotherapy-naive patient with metastatic colorectal cancer Memorial Sloan-Kettering Cancer Center, New York, NY Developing an appropriate treatment strategy.
|
||||
8 |
Neoadjuvant chemotherapy in a patient with metastatic colorectal cancer Clinic for Oncology/Hematology, Klinikum Oldenburg, Oldenburg, Germany Although neoadjuvant chemotherapy poses unique challenges, tumor downsizing followed by hepatic resection may provide a substantial survival advantage.
|
||||
12 |
Second-line treatment in a patient with refractory or recurrent disease Hospital Sírio Libanês, São Paulo, Brazil For sufficiently fit patients who fail to respond or transiently respond to an initial intervention, a survival benefit may be obtained from additional chemotherapy with standard agents.
|
||||
16 |
The elderly patient with potential treatment toxicity The West Clinic, Memphis, TN According to recent study findings, older patients appear to derive the same benefits from chemotherapy as do younger ones, although the unique healthcare needs of seniors must be considered.
|
||||
21 |
Pharmacogenomics of irinotecan Keck School of Medcine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA Many practical issues surrounding pharmacogenomics await resolution before genetic screening for clinically relevant polymorphisms becomes a reality.
|
||||
Editorial support was provided by Adelphi Inc. and was funded by Pfizer Inc. |
|||||
© 2007 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
63 kb